The Pharma Data

DECEMBER 15, 2020

Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. Scientists will be testing a drug class targeting the C-reactive protein (CRP) marker of acute inflammation in the body. They’ll use software that searches available drugs, as well as drug-like compounds.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Pharmaceutical Technology

MARCH 24, 2023

TB is caused by the bacillus Mycobacterium tuberculosis and is transmitted when infected individuals expel bacteria into the air (e.g., In light of World TB day on March 24, the field hopes to overcome some major barriers to the drug development landscape. by coughing). million new cases reported worldwide.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

XTalks

JUNE 21, 2024

The US Food and Drug Administration (FDA) has green-lighted the first pneumonia vaccine specifically designed for adults 50 years of age and older. According to a November 2023 readout, Capvaxive also elicited superior immune responses for ten of the 11 serotypes not covered by Prevnar 20.

FDA Approval 108

FDA Approval Vaccination Vaccine Life Science 108

The Pharma Data

DECEMBER 31, 2020

“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immune response, and others have a more moderate response. There are also other branches of the immune system involved.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. “We NEW YORK–(BUSINESS WIRE)– Pfizer Inc.

Vaccination 52

Vaccination Vaccine FDA Approval Containment 52

XTalks

NOVEMBER 12, 2024

Pneumonia is a lung infection that can be caused by viruses, bacteria or fungi and can result in millions of hospitalizations and deaths annually. Thus, to address drug-resistant infections, pharma and biotech companies are developing novel treatments such as bacteriophage therapies, immunomodulators and monoclonal antibodies.

Bacteria 110

Bacteria Life Science Vaccination Vaccine 110

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Immune Response 52

Immune Response Vaccination Vaccine FDA Approval 52

XTalks

AUGUST 18, 2021

While infectious disease experts and drug companies have rightfully spent the last 18 months developing therapeutics and vaccines targeting SARS-CoV-2 and COVID-19, another global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist until similar direct action is taken.

Development 105

Development Bacteria Drugs Vaccination 105

XTalks

DECEMBER 17, 2021

Developing a highly effective vaccine against malaria has been technically challenging because malaria has a large and complex genome, and it’s why it’s generally more difficult to develop a vaccine against parasites than smaller viruses and bacteria.

Life Science 98

Life Science Vaccination Vaccine Trials 98

XTalks

MARCH 24, 2025

Fabhalta works by inhibiting factor B, a key enzyme in the alternative complement pathway, thus calming the damaging immune response. Due to a risk of serious infections from encapsulated bacteria, its use is limited to a Risk Evaluation and Mitigation Strategy requiring specific vaccinations.

Bioavailability 71

Bioavailability Immune Response Protein Bacteria 71